Our Portfolio

ADmit Therapeutics S.L.

Marta Barrachina, PhD, MBA | Catalunya, Spain

Project Overview

  • Biotechnology/For Profit Organization Type
  • $1,900,000 Funding Amount
  • 2/18/23 — 2/18/26 Project Duration
  • Biomarkers Program
  • Mitochondria/Metabolic Function Target
  • Blood Biomarker Type
  • Active Status

ADmit Therapeutics S.L.

Marta Barrachina, PhD, MBA | Catalunya, Spain

MAP-AD, a revolutionary Methylation Profiling approach for early diagnosis of Alzheimer’s Disease

GET IN TOUCH